ContraFect Awarded $2.1 Million PRMRP Grant to Support Development of CF-301
YONKERS, NY--(Marketwired - November 17, 2016) - ContraFect Corporation (NASDAQ: CFRX) (NASDAQ: CFRXW), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious …